Research groups
Parvinder Aley
Director of Global Operations (OVG)
Parv joined the Oxford Vaccine Group in May 2016. She has a PhD in Cellular Physiology from the University of Leeds. Subsequently she moved to Oxford where she has worked at the University for the past 16 years, initially as a researcher and subsequently as a Contracts Specialist. She played a pivotal role in the clinical trial operations of the Oxford/AZ COVID vaccine development supporting not only the delivery of the trials in UK, Brazil and South Africa, but working with our partners to ensure market authorisation of the vaccine at a global scale.
As Director of Global Operations, she is responsible responsible for the strategic oversight and direction of activity for the Oxford Vaccine Group, with the aim to facilitate research on the development and implementation of vaccines. The role extends to national and international representation the University’s research mission with funders, industry, Governments and policymaker, working closely with collaborators on 5 continents involving more than 1000 researchers, and coordinates considerable logistical operations globally
Recent publications
-
Corrigendum to "Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial" [J Infect 84(6) (2022) 795-813, 5511].
Journal article
Liu X. et al, (2023), J Infect
-
Pneumococcal carriage following PCV13 delivered as one primary and one booster dose (1 + 1) compared to two primary doses and a booster (2 + 1) in UK infants.
Journal article
Goldblatt D. et al, (2023), Vaccine
-
Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - a single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines.
Journal article
Shaw RH. et al, (2023), J Infect
-
Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow up of two randomised controlled trials.
Journal article
Voysey M. et al, (2023), Clin Exp Immunol
-
A Randomized Trial Assessing the Immunogenicity and Reactogenicity of Two Hexavalent Infant Vaccines Concomitantly Administered With Group B Meningococcal Vaccine.
Journal article
Rajan M. et al, (2023), Pediatr Infect Dis J, 42, 66 - 73